The Advantages of Monodisperse PEG In Drug Development?
With advancements in both synthetic and purification chemistry over the past two decades, monodispersed PEG linkers have become more commercially viable. Monodispersed PEG linkers have been found to be beneficial in drug design, specifically in small molecule drugs. Some of the problems that are often seen in small molecule drugs include its ability to be easily removed from the body, low solubility and less target-specificity. The introduction of monodispersed PEG linkers to small molecule drugs increases the drug's solubility and molecular weight. This may allow an extended drug half-life in the body. The use of monodispersed PEG linkers has also improved drug development with its ability to produce homogeneous PEGylated drugs with a specific molecular weight.
Pharmaceutical companies such as NEKTAR and AstraZeneca have made use of attached PEG linkers to small molecule drugs. OBD and OIC medications such as Movantik (naloxol) incorporate monodispersed PEG linkers to enhance the efficacy of the drug. Movantik includes an m-PEG7 linker. The introduction of this linker to Movantik reduced transport across the blood-brain barrier preventing side-effects to the central nervous system.
Biochempeg (https://www.biochempeg.com), founded in 2013, is a biotechnology-
Biochempeg team owns the most qualified and talented synthetic and medicinal chemists. We can provide a wide range of high purity monodispersed PEG products (https://www.biochempeg.com/
With our strong expertise in modern chemistry, innovative & novel PEG technology and state-of-the-
Biochempeg Scientific Inc.
108 Water Street, Room 4D, Watertown, MA 02472, USA